BURLINGTON, Mass., Oct. 30,
2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA)
today announced the launch of a long-read Whole Genome Sequencing
(WGS) test for clinical applications. Azenta becomes the first
commercial provider to obtain regulatory approval to offer this
test in the United States.
Traditional short-read sequencing methods often struggle with
identifying genetic variants in repetitive regions of the genome
that underpin many rare diseases, hindering accurate diagnoses and
targeted treatments. In contrast, Azenta's test makes use of
PacBio's Revio sequencer to obtain long and highly accurate HiFi
sequencing reads to cover regions that are inaccessible by short
reads. Performed within GENEWIZ from Azenta Life Sciences CLIA
certified and CAP accredited state-of-the-art clinical
genomics laboratory, the test enables precise detection of a range
of complex genomic alterations that are features of many rare
diseases and undetectable by traditional approaches. This allows
for a view of the genome with unprecedented comprehensiveness.
"Clinical-grade long-read sequencing represents a monumental
leap forward in the ability to decipher the genetic basis of rare
diseases. By capturing long stretches of DNA in a single read,
researchers can uncover subtle genetic nuances that were previously
undetectable with conventional methods," said Dr. Ginger Zhou, Senior Vice President & General
Manager – GENEWIZ Multiomics and Synthesis Solutions from Azenta
Life Sciences. "This capability not only enhances diagnostic
accuracy but also opens new avenues for developing targeted
therapies and conducting more effective clinical trials."
"Azenta's test highlights the power of PacBio's technology in
generating the most accurate and comprehensive genomic data
available today," said Christian
Henry, President and Chief Executive Officer of PacBio.
"Revio's highly accurate HiFi reads are having an increasingly
significant impact, allowing researchers to uncover the complex
intricacies of rare diseases. We are proud to support their
innovative work in expanding what's possible in clinical
applications with these deeper, more precise views of the
genome."
Learn about our Long-Read Whole Genome Sequencing Test by
visiting us at booth #422 at the American Society of Human Genetics
(ASHG) Conference on November 5-9 in
Denver, CO. For more information,
please visit
https://www.genewiz.com/en/Public/Services/Clinical-Services
About Azenta Life Sciences
Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life
sciences solutions worldwide, enabling impactful breakthroughs and
therapies to market faster. Azenta provides a full suite of
reliable cold-chain sample management solutions and multiomics
services across areas such as drug development, clinical research
and advanced cell therapies for the industry's top pharmaceutical,
biotech, academic and healthcare institutions globally. Our global
team delivers and supports these products and services through our
industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude,
Limfinity, Freezer Pro, Barkey and B Medical Systems.
Azenta is headquartered in Burlington, MA, with operations
in North America, Europe and Asia. For more
information, please visit www.azenta.com.
"Safe Harbor Statement" under Section 21E of the Securities
Exchange Act of 1934
Some statements in this release are forward-looking statements
made under Section 21E of the Securities Exchange Act of 1934.
These statements are neither promises nor guarantees but involve
risks and uncertainties, both known and unknown, that could cause
Azenta's financial and business results to differ materially from
our expectations. They are based on the facts known to management
at the time they are made. Forward-looking statements include but
are not limited to statements about the potential benefits of
Azenta's long-read Whole Genome Sequencing (WGS) test for clinical
applications. Factors that could cause results to differ from
our expectations include the following: our ability to perform the
long-read WGS test, the performance of the sequencing equipment
used in conducting the long-read WGS test, and the ability of our
customers to develop new therapies using the long-read WGS test and
other factors and other risks, including those that we have
described in our filings with the Securities and Exchange
Commission, including but not limited to our Annual Report on Form
10-K, Current Reports on Form 8-K and our Quarterly Reports on Form
10-Q. As a result, we can provide no assurance that our future
results will not be materially different from those projected.
Azenta expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any such statement to reflect
any change in our expectations or any change in events, conditions,
or circumstances on which any such statement is based. Azenta
undertakes no obligation to update the information contained in
this press release.
INVESTOR CONTACTS:
Yvonne Perron
Vice President, Financial, Planning & Analysis and Investor
Relations
ir@azenta.com
Sherry Dinsmore
sherry.dinsmore@azenta.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/azenta-obtains-regulatory-approval-for-clinical-long-read-whole-genome-sequencing-test-302292009.html
SOURCE Azenta
